Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research – Diabetes and Obesity

Volume 4

eBook: US $79 Special Offer (PDF + Printed Copy): US $158
Printed Copy: US $119
Library License: US $316
ISSN: 2467-9607 (Print)
ISSN: 2352-3220 (Online)
ISBN: 978-1-68108-446-6 (Print)
ISBN: 978-1-68108-445-9 (Online)
Year of Publication: 2019
DOI: 10.2174/97816810844591170401

Introduction

Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The fourth volume of this series features 7 chapters:

  • -Pharmacologic Obesity Treatment
  • -Interplay Between Bile Acid and GLP-1 Receptor Agonist Signaling Informs the Design of Drugs to Combat Obesity and its Metabolic Complications
  • -Sodium–Glucose Co-Transporters Inhibitors for Type 2 Diabetes Mellitus
  • -The Effects of Traditional Chinese Medicine on Inflammatory Cytokines in Diabetic Nephropathy
  • -Through the Perspective of Histology – The Alzheimer’s Disease Promotion by Obesity and Glucose Metabolism: Type 3 Diabetes
  • -Pharmacological Mechanism of PPARγ Ratio in Diabetes and Obesity
  • -Hydrogen Sulfide and Carbohydrate Metabolism

Preface

This volume of the eBook series entitled: Frontiers in Clinical Drug Research – Diabetes and Obesity presents some recent exciting developments in clinical trials and formulation of research plans in the field of diabetes and obesity. The book should prove to be a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials.

The chapters are written by authorities in the field and are mainly focused on obesity treatment. They include contributions on cardiometabolic markers, bile acid and GLP-1 receptor agonists to combat obesity and its metabolic complications, sodium-glucose co-transporter inhibitors for type 2 diabetes mellitus, the effects of traditional Chinese medicine on inflammatory cytokines in diabetic nephropathy, Alzheimer’s disease promotion by obesity and glucose metabolism, pharmacological mechanism of PPARγ ratio in diabetes and obesity, and the metabolism of hydrogen sulfide and carbohydrate.

I hope that the readers will find these reviews valuable and thought-provoking so that they may trigger further research in the quest for new developments in the field. I am thankful to the efficient team of Bentham Science Publishers especially Dr. Faryal Sami (Manager Publications), Mr. Shehzad Iqbal Naqvi (Editorial Manager Publications) and Mr. Mahmood Alam (Director Publications).

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

RELATED BOOKS

.Phytotherapy in the Management of Diabetes and Hypertension.
.Phytotherapy in the Management of Diabetes and Hypertension.
.Frontiers in Clinical Drug Research – Diabetes and Obesity.
.Understanding Obesity: From its Causes to Impact on Life.